Comments
Bharat Biotech International is working ‘diligently’ on obtaining Emergency Use Listing (EUL) for its Covid-19 vaccine, Covaxin, from the World Health Organisation (WHO) at the earliest.
Bharat Biotech’s intranasal shot can be a booster dose to vaccination programme
The clinical trial data of Covaxin were compiled and available in June. “All the data were submitted for EUL application to WHO in July,’’ the Hyderabad-based company said on Friday. Bharat Biotech has also responded to the clarifications sought by WHO and is awaiting further feedback.
“As a responsible manufacturer with several WHO pre-qualified vaccines, we do not find it appropriate to speculate or comment on approval process and its timeliness,’’ the company said, adding that it was continuing to work diligently on obtaining WHO EUL for Covaxin “at the earliest.’’
Comments
COMMENT NOW
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.